(Q34805056)

4 August 2017

1 reference

title

Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs (English)

1 reference

4 August 2017

Dan L Eisenberg

1

1 reference

4 August 2017

Carol B Toris

series ordinal

2

1 reference

4 August 2017

Carl B Camras

series ordinal

3

1 reference

4 August 2017

publication date

1 August 2002

1 reference

4 August 2017

published in

Survey of Ophthalmology

1 reference

4 August 2017

volume

47 Suppl 1

1 reference

4 August 2017

page(s)

S105-15

1 reference

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Bimatoprost vs. timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Potent luteolytic agents related to prostaglandin F2α

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects of topical anandamides on intraocular pressure in normotensive rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Bimatoprost and its free acid are prostaglandin FP receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Effects of prostaglandins on the aqueous humor outflow pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

The pharmacology of bimatoprost (Lumigan).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900327-2

7 January 2021

10.1016/S0039-6257(02)00327-2

Identifiers

DOI

1 reference

4 August 2017

1 reference